The management of diabetes mellitus by mangiferin: advances and prospects.

Wang, Mengdi; Liang, Yan; Chen, Keqi; Wang, Maolong; Long, Xuehua; Liu, HongLing; Sun, Yong; He, Bin

Wang, Mengdi; Liang, Yan; Chen, Keqi; Wang, Maolong; Long, Xuehua; Liu, HongLing; Sun, Yong; He, Bin.

Afiliación

Wang M; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266073, China. sunyong@qdu.edu.cn.
Liang Y; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266073, China. sunyong@qdu.edu.cn.
Chen K; Department of Clinical laboratory, Qingdao special servicemen recuperation centre of PLA navy, Qingdao 266021, China.
Wang M; Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao 266000, China.
Long X; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266073, China. sunyong@qdu.edu.cn.
Liu H; Department of Pharmacy, Affiliated Hospital of Qingdao University, Qingdao 266000, China. lhl3798@126.com.
Sun Y; Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266073, China. sunyong@qdu.edu.cn.
He B; National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China.

Nanoscale ; 14(6): 2119-2135, 2022 Feb 10.

Article en En | MEDLINE | ID: mdl-35088781

Asunto(s)

Diabetes Mellitus; Xantonas; Disponibilidad Biológica; Diabetes Mellitus/tratamiento farmacológico; Humanos; Solubilidad; Xantonas/uso terapéutico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Xantonas / Diabetes Mellitus Tipo de estudio: Risk_factors_studies Límite: Humans Idioma: En Revista: Nanoscale Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google